{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T16:36:19Z","timestamp":1782923779138,"version":"3.54.5"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,6,21]],"date-time":"2021-06-21T00:00:00Z","timestamp":1624233600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,6,21]],"date-time":"2021-06-21T00:00:00Z","timestamp":1624233600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Hypoxia is prominent in solid tumors and a recognized driver of malignancy. Thus far, targeting tumor hypoxia has remained unsuccessful. Myo-inositol trispyrophosphate (ITPP) is a re-oxygenating compound without apparent toxicity. In preclinical models, ITPP potentiates the efficacy of subsequent chemotherapy through vascular normalization. Here, we report the results of an unrandomized, open-labeled, 3\u2009+\u20093 dose-escalation phase Ib study (NCT02528526) including 28 patients with advanced primary hepatopancreatobiliary malignancies and liver metastases of colorectal cancer receiving nine 8h-infusions of ITPP over three weeks across eight dose levels (1'866-14'500\u2009mg\/m<jats:sup>2<\/jats:sup>\/dose), followed by standard chemotherapy. Primary objectives are assessment of the safety and tolerability and establishment of the maximum tolerated dose, while secondary objectives include assessment of pharmacokinetics, antitumor activity via radiological evaluation and assessment of circulatory tumor-specific and angiogenic markers. The maximum tolerated dose is 12,390\u2009mg\/m<jats:sup>2<\/jats:sup>, and ITPP treatment results in 32 treatment-related toxicities (mostly hypercalcemia) that require little or no intervention. 52% of patients have morphological disease stabilization under ITPP monotherapy. Following subsequent chemotherapy, 10% show partial responses while 60% have stable disease. Decreases in angiogenic markers are noted in \u223c60% of patients after ITPP and tend to correlate with responses and survival after chemotherapy.<\/jats:p>","DOI":"10.1038\/s41467-021-24069-w","type":"journal-article","created":{"date-parts":[[2021,6,21]],"date-time":"2021-06-21T10:03:10Z","timestamp":1624269790000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Phase Ib dose-escalation study of the hypoxia-modifier Myo-inositol trispyrophosphate in patients with hepatopancreatobiliary tumors"],"prefix":"10.1038","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6723-8879","authenticated-orcid":false,"given":"Marcel A.","family":"Schneider","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Linecker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph","family":"Fritsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3423-4633","authenticated-orcid":false,"given":"Urs J.","family":"Muehlematter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Stocker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernhard","family":"Pestalozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panagiotis","family":"Samaras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7394-2192","authenticated-orcid":false,"given":"Alexander","family":"Jetter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Kron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Petrowsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claude","family":"Nicolau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Marie","family":"Lehn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bostjan","family":"Humar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7449-7302","authenticated-orcid":false,"given":"Rolf","family":"Graf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre-Alain","family":"Clavien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4158-4666","authenticated-orcid":false,"given":"Perparim","family":"Limani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,6,21]]},"reference":[{"key":"24069_CR1","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/nature04871","volume":"441","author":"J Pouyssegur","year":"2006","unstructured":"Pouyssegur, J., Dayan, F. & Mazure, N. M. Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature 441, 437\u2013443 (2006).","journal-title":"Nature"},{"key":"24069_CR2","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1038\/s41588-018-0318-2","volume":"51","author":"V Bhandari","year":"2019","unstructured":"Bhandari, V. et al. Molecular landmarks of tumor hypoxia across cancer types. Nat. Genet. 51, 308\u2013318 (2019).","journal-title":"Nat. Genet."},{"key":"24069_CR3","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1038\/nrclinonc.2011.83","volume":"8","author":"K De Bock","year":"2011","unstructured":"De Bock, K., Mazzone, M. & Carmeliet, P. Antiangiogenic therapy, hypoxia, and metastasis: risky liaisons, or not? Nat. Rev. Clin. Oncol. 8, 393\u2013404 (2011).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"24069_CR4","doi-asserted-by":"publisher","first-page":"C569","DOI":"10.1152\/ajpcell.00207.2015","volume":"309","author":"MZ Noman","year":"2015","unstructured":"Noman, M. Z. et al. Hypoxia: a key player in antitumor immune response. A review in the theme: cellular responses to hypoxia. Am. J. Physiol. Cell Physiol. 309, C569\u2013C579 (2015).","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"24069_CR5","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1089\/ars.2013.5378","volume":"21","author":"JC Walsh","year":"2014","unstructured":"Walsh, J. C. et al. The clinical importance of assessing tumor hypoxia: relationship of tumor hypoxia to prognosis and therapeutic opportunities. Antioxid. Redox Signal. 21, 1516\u20131554 (2014).","journal-title":"Antioxid. Redox Signal."},{"key":"24069_CR6","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1056\/NEJMra0706596","volume":"358","author":"RS Kerbel","year":"2008","unstructured":"Kerbel, R. S. Tumor angiogenesis. N. Engl. J. Med. 358, 2039\u20132049 (2008).","journal-title":"N. Engl. J. Med."},{"key":"24069_CR7","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1038\/nrc3064","volume":"11","author":"WR Wilson","year":"2011","unstructured":"Wilson, W. R. & Hay, M. P. Targeting hypoxia in cancer therapy. Nat. Rev. Cancer 11, 393\u2013410 (2011).","journal-title":"Nat. Rev. Cancer"},{"key":"24069_CR8","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.molcel.2010.09.022","volume":"40","author":"AJ Majmundar","year":"2010","unstructured":"Majmundar, A. J., Wong, W. J. & Simon, M. C. Hypoxia-inducible factors and the response to hypoxic stress. Mol. cell 40, 294\u2013309 (2010).","journal-title":"Mol. cell"},{"key":"24069_CR9","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1056\/NEJMra0910283","volume":"364","author":"HK Eltzschig","year":"2011","unstructured":"Eltzschig, H. K. & Carmeliet, P. Hypoxia and inflammation. N. Engl. J. Med 364, 656\u2013665 (2011).","journal-title":"N. Engl. J. Med"},{"key":"24069_CR10","doi-asserted-by":"publisher","first-page":"4","DOI":"10.3389\/fcell.2019.00004","volume":"7","author":"W Al Tameemi","year":"2019","unstructured":"Al Tameemi, W., Dale, T. P., Al-Jumaily, R. M. K. & Forsyth, N. R. Hypoxia-modified cancer cell metabolism. Front Cell Dev. Biol. 7, 4 (2019).","journal-title":"Front Cell Dev. Biol."},{"key":"24069_CR11","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1126\/science.aaf4405","volume":"352","author":"EB Rankin","year":"2016","unstructured":"Rankin, E. B. & Giaccia, A. J. Hypoxic control of metastasis. Science 352, 175\u2013180 (2016).","journal-title":"Science"},{"key":"24069_CR12","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.trecan.2016.05.006","volume":"2","author":"EB Rankin","year":"2016","unstructured":"Rankin, E. B., Nam, J. M. & Giaccia, A. J. Hypoxia: signaling the metastatic cascade. Trends Cancer 2, 295\u2013304 (2016).","journal-title":"Trends Cancer"},{"key":"24069_CR13","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1084\/jem.20131916","volume":"211","author":"MZ Noman","year":"2014","unstructured":"Noman, M. Z. et al. PD-L1 is a novel direct target of HIF-1\u03b1, and its blockade under hypoxia enhanced MDSC-mediated T cell activation. J. Exp. Med. 211, 781\u2013790 (2014).","journal-title":"J. Exp. Med."},{"key":"24069_CR14","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1038\/onc.2016.225","volume":"36","author":"S Chouaib","year":"2017","unstructured":"Chouaib, S., Noman, M. Z., Kosmatopoulos, K. & Curran, M. A. Hypoxic stress: obstacles and opportunities for innovative immunotherapy of cancer. Oncogene 36, 439\u2013445 (2017).","journal-title":"Oncogene"},{"key":"24069_CR15","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646\u2013674 (2011).","journal-title":"Cell"},{"key":"24069_CR16","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1038\/s42255-019-0045-8","volume":"1","author":"Y Ye","year":"2019","unstructured":"Ye, Y. et al. Characterization of hypoxia-associated molecular features to aid hypoxia-targeted therapy. Nat. Metab. 1, 431\u2013444 (2019).","journal-title":"Nat. Metab."},{"key":"24069_CR17","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1056\/NEJMoa032691","volume":"350","author":"H Hurwitz","year":"2004","unstructured":"Hurwitz, H. et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 350, 2335\u20132342 (2004).","journal-title":"N. Engl. J. Med."},{"key":"24069_CR18","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.ccr.2009.01.027","volume":"15","author":"M Paez-Ribes","year":"2009","unstructured":"Paez-Ribes, M. et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 15, 220\u2013231 (2009).","journal-title":"Cancer Cell"},{"key":"24069_CR19","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1158\/1535-7163.233.3.3","volume":"3","author":"S Welsh","year":"2004","unstructured":"Welsh, S., Williams, R., Kirkpatrick, L., Paine-Murrieta, G. & Powis, G. Antitumor activity and pharmacodynamic properties of PX-478, an inhibitor of hypoxia-inducible factor-1alpha. Mol. Cancer Therapeutics 3, 233\u2013244 (2004).","journal-title":"Mol. Cancer Therapeutics"},{"key":"24069_CR20","doi-asserted-by":"publisher","first-page":"2250","DOI":"10.18632\/oncotarget.2948","volume":"6","author":"T Zhao","year":"2015","unstructured":"Zhao, T. et al. Inhibition of HIF-1\u03b1 by PX-478 enhances the anti-tumor effect of gemcitabine by inducing immunogenic cell death in pancreatic ductal adenocarcinoma. Oncotarget 6, 2250\u20132262 (2015).","journal-title":"Oncotarget"},{"key":"24069_CR21","doi-asserted-by":"publisher","first-page":"2057","DOI":"10.1158\/1535-7163.MCT-09-0768","volume":"9","author":"DL Schwartz","year":"2010","unstructured":"Schwartz, D. L. et al. Radiosensitization and stromal imaging response correlates for the HIF-1 inhibitor PX-478 given with or without chemotherapy in pancreatic cancer. Mol. Cancer Therapeutics 9, 2057\u20132067 (2010).","journal-title":"Mol. Cancer Therapeutics"},{"key":"24069_CR22","doi-asserted-by":"publisher","first-page":"3076","DOI":"10.1200\/jco.2010.28.15_suppl.3076","volume":"28","author":"R Tibes","year":"2010","unstructured":"Tibes, R. et al. Results from a phase I, dose-escalation study of PX-478, an orally available inhibitor of HIF-1\u03b1. J. Clin. Oncol. 28, 3076\u20133076 (2010).","journal-title":"J. Clin. Oncol."},{"key":"24069_CR23","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1200\/JCO.2014.55.7504","volume":"33","author":"MJ Borad","year":"2015","unstructured":"Borad, M. J. et al. Randomized phase II trial of gemcitabine plus TH-302 versus gemcitabine in patients with advanced pancreatic cancer. J. Clin. Oncol. 33, 1475\u20131481 (2015).","journal-title":"J. Clin. Oncol."},{"key":"24069_CR24","doi-asserted-by":"publisher","unstructured":"Kishimoto S. et al. Hypoxia-activated prodrug evofosfamide treatment in pancreatic ductal adenocarcinoma xenografts alters the tumor redox status to potentiate radiotherapy. Antioxid. Redox Signal. https:\/\/doi.org\/10.1089\/ars.2020.8131 (2020). Accession Number: 32787454.","DOI":"10.1089\/ars.2020.8131"},{"key":"24069_CR25","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1080\/15384047.2014.1003005","volume":"16","author":"JD Sun","year":"2015","unstructured":"Sun, J. D. et al. Efficacy and safety of the hypoxia-activated prodrug TH-302 in combination with gemcitabine and nab-paclitaxel in human tumor xenograft models of pancreatic cancer. Cancer Biol. Ther. 16, 438\u2013449 (2015).","journal-title":"Cancer Biol. Ther."},{"key":"24069_CR26","doi-asserted-by":"crossref","unstructured":"Yoon, J., Kang, S. Y., Lee, K. H., Cheon, G. J., Oh, D. Y. Targeting hypoxia using evofosfamide and companion hypoxia imaging of FMISO-PET in advanced biliary tract cancer. Cancer Res. Treatment 53, 471\u2013479 (2021).","DOI":"10.4143\/crt.2020.577"},{"key":"24069_CR27","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1158\/1078-0432.CCR-16-0725","volume":"23","author":"R Duran","year":"2017","unstructured":"Duran, R. et al. Preclinical benefit of hypoxia-activated intra-arterial therapy with evofosfamide in liver cancer. Clin. Cancer Res. 23, 536\u2013548 (2017).","journal-title":"Clin. Cancer Res."},{"key":"24069_CR28","doi-asserted-by":"publisher","first-page":"2116","DOI":"10.1158\/1078-0432.CCR-17-1715","volume":"24","author":"J Haynes","year":"2018","unstructured":"Haynes, J. et al. Administration of hypoxia-activated prodrug evofosfamide after conventional adjuvant therapy enhances therapeutic outcome and targets cancer-initiating cells in preclinical models of colorectal cancer. Clin. Cancer Res 24, 2116\u20132127 (2018).","journal-title":"Clin. Cancer Res"},{"key":"24069_CR29","doi-asserted-by":"publisher","first-page":"3299","DOI":"10.1200\/JCO.2013.54.3660","volume":"32","author":"SP Chawla","year":"2014","unstructured":"Chawla, S. P. et al. Phase II study of the safety and antitumor activity of the hypoxia-activated prodrug TH-302 in combination with doxorubicin in patients with advanced soft tissue sarcoma. J. Clin. Oncol. 32, 3299\u20133306 (2014).","journal-title":"J. Clin. Oncol."},{"key":"24069_CR30","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1159\/000327739","volume":"80","author":"KN Ganjoo","year":"2011","unstructured":"Ganjoo, K. N. et al. A phase I study of the safety and pharmacokinetics of the hypoxia-activated prodrug TH-302 in combination with doxorubicin in patients with advanced soft tissue sarcoma. Oncology 80, 50\u201356 (2011).","journal-title":"Oncology"},{"key":"24069_CR31","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1158\/1078-0432.CCR-11-1980","volume":"18","author":"JD Sun","year":"2012","unstructured":"Sun, J. D. et al. Selective tumor hypoxia targeting by hypoxia-activated prodrug TH-302 inhibits tumor growth in preclinical models of cancer. Clin. Cancer Res. 18, 758\u2013770 (2012).","journal-title":"Clin. Cancer Res."},{"key":"24069_CR32","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1016\/S1470-2045(17)30381-9","volume":"18","author":"WD Tap","year":"2017","unstructured":"Tap, W. D. et al. Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406\/SARC021): an international, multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 18, 1089\u20131103 (2017).","journal-title":"Lancet Oncol."},{"key":"24069_CR33","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1038\/bjc.2016.386","volume":"116","author":"L Welsh","year":"2017","unstructured":"Welsh, L. et al. Blood transfusion during radical chemo-radiotherapy does not reduce tumour hypoxia in squamous cell cancer of the head and neck. Br. J. Cancer 116, 28\u201335 (2017).","journal-title":"Br. J. Cancer"},{"key":"24069_CR34","doi-asserted-by":"publisher","first-page":"2280","DOI":"10.1093\/annonc\/mdv373","volume":"26","author":"A Davidson","year":"2015","unstructured":"Davidson, A. et al. A phase III randomized trial of adding topical nitroglycerin to first-line chemotherapy for advanced nonsmall-cell lung cancer: the Australasian lung cancer trials group NITRO trial. Ann. Oncol. 26, 2280\u20132286 (2015).","journal-title":"Ann. Oncol."},{"key":"24069_CR35","doi-asserted-by":"publisher","first-page":"3115","DOI":"10.1158\/1078-0432.CCR-05-0513","volume":"12","author":"N Gupta","year":"2006","unstructured":"Gupta, N. et al. Carbogen and nicotinamide increase blood flow and 5-fluorouracil delivery but not 5-fluorouracil retention in colorectal cancer metastases in patients. Clin. Cancer Res. 12, 3115\u20133123 (2006).","journal-title":"Clin. Cancer Res."},{"key":"24069_CR36","first-page":"33","volume":"33","author":"SD Heys","year":"2006","unstructured":"Heys, S. D. et al. A pilot study with long term follow up of hyperbaric oxygen pretreatment in patients with locally advanced breast cancer undergoing neo-adjuvant chemotherapy. Undersea Hyperbaric Med. 33, 33\u201343 (2006).","journal-title":"Undersea Hyperbaric Med."},{"key":"24069_CR37","doi-asserted-by":"publisher","first-page":"2543","DOI":"10.1002\/cbic.201000499","volume":"11","author":"CD Duarte","year":"2010","unstructured":"Duarte, C. D., Greferath, R., Nicolau, C. & Lehn, J. M. myo-Inositol trispyrophosphate: a novel allosteric effector of hemoglobin with high permeation selectivity across the red blood cell plasma membrane. Chembiochem 11, 2543\u20132548 (2010).","journal-title":"Chembiochem"},{"key":"24069_CR38","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1007\/s00109-013-0992-6","volume":"91","author":"C Kieda","year":"2013","unstructured":"Kieda, C. et al. Stable tumor vessel normalization with pO2 increase and endothelial PTEN activation by inositol trispyrophosphate brings novel tumor treatment. J. Mol. Med. 91, 883\u2013899 (2013).","journal-title":"J. Mol. Med."},{"key":"24069_CR39","doi-asserted-by":"publisher","first-page":"2572","DOI":"10.1002\/ijc.28597","volume":"134","author":"Z Raykov","year":"2014","unstructured":"Raykov, Z. et al. Myo-inositol trispyrophosphate-mediated hypoxia reversion controls pancreatic cancer in rodents and enhances gemcitabine efficacy. Int. J. Cancer 134, 2572\u20132582 (2014).","journal-title":"Int. J. Cancer"},{"key":"24069_CR40","doi-asserted-by":"publisher","first-page":"5887","DOI":"10.1158\/1078-0432.CCR-15-3112","volume":"22","author":"P Limani","year":"2016","unstructured":"Limani, P. et al. Antihypoxic potentiation of standard therapy for experimental colorectal liver metastasis through myo-inositol trispyrophosphate. Clin. Cancer Res. 22, 5887\u20135897 (2016).","journal-title":"Clin. Cancer Res."},{"key":"24069_CR41","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1097\/SLA.0000000000002431","volume":"266","author":"P Limani","year":"2017","unstructured":"Limani, P. et al. The allosteric hemoglobin effector ITPP inhibits metastatic colon cancer in mice. Ann. Surg. 266, 746\u2013753 (2017).","journal-title":"Ann. Surg."},{"key":"24069_CR42","doi-asserted-by":"publisher","first-page":"4313","DOI":"10.1038\/onc.2012.445","volume":"32","author":"L Derbal-Wolfrom","year":"2013","unstructured":"Derbal-Wolfrom, L. et al. Increasing the oxygen load by treatment with myo-inositol trispyrophosphate reduces growth of colon cancer and modulates the intestine homeobox gene Cdx2. Oncogene 32, 4313\u20134318 (2013).","journal-title":"Oncogene"},{"key":"24069_CR43","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1002\/cbic.201000619","volume":"12","author":"M Aprahamian","year":"2011","unstructured":"Aprahamian, M. et al. Myo-InositolTrisPyroPhosphate treatment leads to HIF-1\u03b1 suppression and eradication of early hepatoma tumors in rats. Chembiochem 12, 777\u2013783 (2011).","journal-title":"Chembiochem"},{"key":"24069_CR44","doi-asserted-by":"publisher","first-page":"e50860","DOI":"10.1371\/journal.pone.0050860","volume":"7","author":"B Bao","year":"2012","unstructured":"Bao, B. et al. In vivo imaging and quantification of carbonic anhydrase IX expression as an endogenous biomarker of tumor hypoxia. PLoS ONE 7, e50860 (2012).","journal-title":"PLoS ONE"},{"key":"24069_CR45","doi-asserted-by":"crossref","unstructured":"Tafreshi N. K., Lloyd M. C., Bui M. M., Gillies R. J., Morse D. L. Carbonic anhydrase IX as an imaging and therapeutic target for tumors and metastases. In: Carbonic Anhydrase: Mechanism, Regulation, Links to Disease, and Industrial Applications (eds. Frost, S. C. and McKenna, R.) (Springer Netherlands, 2014).","DOI":"10.1007\/978-94-007-7359-2_12"},{"key":"24069_CR46","doi-asserted-by":"publisher","first-page":"43356","DOI":"10.18632\/oncotarget.17445","volume":"8","author":"M Yu","year":"2017","unstructured":"Yu, M. et al. The prognostic value of GLUT1 in cancers: a systematic review and meta-analysis. Oncotarget 8, 43356\u201343367 (2017).","journal-title":"Oncotarget"},{"key":"24069_CR47","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.vph.2016.05.003","volume":"86","author":"AV Shah","year":"2016","unstructured":"Shah, A. V., Birdsey, G. M. & Randi, A. M. Regulation of endothelial homeostasis, vascular development and angiogenesis by the transcription factor ERG. Vasc. Pharmacol. 86, 3\u201313 (2016).","journal-title":"Vasc. Pharmacol."},{"key":"24069_CR48","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1073\/pnas.0812381106","volume":"106","author":"A Biolo","year":"2009","unstructured":"Biolo, A. et al. Enhanced exercise capacity in mice with severe heart failure treated with an allosteric effector of hemoglobin, myo-inositol trispyrophosphate. Proc. Natl Acad. Sci. USA 106, 1926\u20131929 (2009).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"24069_CR49","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1038\/nrc2868","volume":"10","author":"AS Chung","year":"2010","unstructured":"Chung, A. S., Lee, J. & Ferrara, N. Targeting the tumour vasculature: insights from physiological angiogenesis. Nat. Rev. Cancer 10, 505\u2013514 (2010).","journal-title":"Nat. Rev. Cancer"},{"key":"24069_CR50","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.canlet.2012.08.018","volume":"328","author":"E Fagiani","year":"2013","unstructured":"Fagiani, E. & Christofori, G. Angiopoietins in angiogenesis. Cancer Lett. 328, 18\u201326 (2013).","journal-title":"Cancer Lett."},{"key":"24069_CR51","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-13-518","volume":"13","author":"TL Khong","year":"2013","unstructured":"Khong, T. L. et al. Identification of the angiogenic gene signature induced by EGF and hypoxia in colorectal cancer. BMC Cancer 13, 518 (2013).","journal-title":"BMC Cancer"},{"key":"24069_CR52","doi-asserted-by":"publisher","first-page":"e0205851","DOI":"10.1371\/journal.pone.0205851","volume":"13","author":"N Zafar","year":"2018","unstructured":"Zafar, N. et al. Circulating angiogenic stem cells in type 2 diabetes are associated with glycemic control and endothelial dysfunction. PLoS ONE 13, e0205851 (2018).","journal-title":"PLoS ONE"},{"key":"24069_CR53","doi-asserted-by":"publisher","unstructured":"Liu Z., et al. CD31-labeled circulating endothelial cells as predictor in anlotinib-treated non-small-cell lung cancer: analysis on ALTER-0303 study. Cancer Med. https:\/\/doi.org\/10.1002\/cam4.1584 (2018). Accession Number: 29856135.","DOI":"10.1002\/cam4.1584"},{"key":"24069_CR54","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1158\/0008-5472.CAN-06-4744","volume":"67","author":"MW Dewhirst","year":"2007","unstructured":"Dewhirst, M. W. Intermittent hypoxia furthers the rationale for hypoxia-inducible factor-1 targeting. Cancer Res. 67, 854\u2013855 (2007).","journal-title":"Cancer Res."},{"key":"24069_CR55","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-016-2855-3","volume":"16","author":"P Limani","year":"2016","unstructured":"Limani, P. et al. Development of OXY111A, a novel hypoxia-modifier as a potential antitumor agent in patients with hepato-pancreato-biliary neoplasms - Protocol of a first Ib\/IIa clinical trial. BMC Cancer 16, 812 (2016).","journal-title":"BMC Cancer"},{"key":"24069_CR56","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer, E. A. et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer 45, 228\u2013247 (2009).","journal-title":"Eur. J. Cancer"},{"key":"24069_CR57","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1016\/S0959-8049(99)00229-4","volume":"35","author":"H Young","year":"1999","unstructured":"Young, H. et al. Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur. J. Cancer 35, 1773\u20131782 (1999).","journal-title":"Eur. J. Cancer"},{"key":"24069_CR58","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1038\/nmeth.2089","volume":"9","author":"CA Schneider","year":"2012","unstructured":"Schneider, C. A., Rasband, W. S. & Eliceiri, K. W. NIH Image to ImageJ: 25 years of image analysis. Nat. Methods 9, 671\u2013675 (2012).","journal-title":"Nat. Methods"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-24069-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-24069-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-24069-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,2]],"date-time":"2022-12-02T13:24:02Z","timestamp":1669987442000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-24069-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,21]]},"references-count":58,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["24069"],"URL":"https:\/\/doi.org\/10.1038\/s41467-021-24069-w","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,21]]},"assertion":[{"value":"22 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study adhered to and was conducted according to the principles of the Declaration of Helsinki and current good clinical practice guidelines. The protocol was approved by the responsible ethics committee of the canton of Zurich, Switzerland (KEK-ZH-Nr. 2014-0374) and the national regulatory authority Swissmedic (2015DR1009) and was registered at ClinicalTrials.gov (NCT02528526) before study start. All patients provided written informed consent before study participation, including consent for publication of individual anonymized data.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"C.N. is co-founder, director, and member of the scientific advisory board of NormOxys \u00ae, Inc. and J.-M.L. is co-founder and chairman of scientific advisory board of NormOxys \u00ae, Inc, this being the company that holds the patent on ITPP. M.A.S., P.L., R.G., B.H. and P.-A.C. had access to raw data. The study drug was provided by NormOxys \u00ae, Inc, free of charge. Neither NormOxys \u00ae, Inc nor any other funding source were involved in study design, patient recruitment\/care, data collection, analysis\/interpretation, or manuscript writing. The remaining authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"3807"}}